CHINA SXT PHARMACEUTICALS IN(NASDAQ:SXTC) stock Fundamental Analysis

Fundamental Rating

Overall SXTC gets a fundamental rating of 3 out of 10. We evaluated SXTC against 198 industry peers in the Pharmaceuticals industry. While SXTC is still in line with the averages on profitability rating, there are concerns on its financial health. SXTC does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SXTC was profitable.

SXTC had a negative operating cash flow in the past year.

In the past 5 years SXTC always reported negative net income.

In multiple years SXTC reported negative operating cash flow during the last 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of 18.70%, SXTC belongs to the top of the industry, outperforming 97.98% of the companies in the same industry.

Looking at the Return On Equity, with a value of 38.54%, SXTC belongs to the top of the industry, outperforming 96.97% of the companies in the same industry.

The Return On Invested Capital of SXTC (30.29%) is better than 97.47% of its industry peers.

		Industry Rank	Sector Rank
ROA	18.7%
ROE	38.54%
ROIC	30.29%

ROA(3y)-16.86%

ROA(5y)-21.19%

ROE(3y)-32.52%

ROE(5y)-44.85%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin of SXTC (318.69%) is better than 98.99% of its industry peers.

SXTC's Operating Margin of 340.71% is amongst the best of the industry. SXTC outperforms 100.00% of its industry peers.

Looking at the Gross Margin, with a value of 22.02%, SXTC is in line with its industry, outperforming 52.53% of the companies in the same industry.

SXTC's Gross Margin has declined in the last couple of years.

		Industry Rank	Sector Rank
OM	340.71%
PM (TTM)	318.69%
GM	22.02%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-21.51%

GM growth 5Y-15.27%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SXTC has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.

SXTC has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, SXTC has more shares outstanding

Compared to 1 year ago, SXTC has an improved debt to assets ratio.

2.2 Solvency

SXTC has an Altman-Z score of -0.13. This is a bad value and indicates that SXTC is not financially healthy and even has some risk of bankruptcy.

SXTC has a Altman-Z score (-0.13) which is in line with its industry peers.

SXTC has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.

With a Debt to Equity ratio value of 0.06, SXTC perfoms like the industry average, outperforming 56.06% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF	N/A
Altman-Z	-0.13

ROIC/WACC5.3

WACC5.71%

2.3 Liquidity

SXTC has a Current Ratio of 1.40. This is a normal value and indicates that SXTC is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 1.40, SXTC is doing worse than 74.24% of the companies in the same industry.

SXTC has a Quick Ratio of 1.35. This is a normal value and indicates that SXTC is financially healthy and should not expect problems in meeting its short term obligations.

SXTC has a worse Quick ratio (1.35) than 67.68% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.4
Quick Ratio	1.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SXTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 124.73%, which is quite impressive.

The Revenue has been growing slightly by 6.99% in the past year.

SXTC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -22.75% yearly.

EPS 1Y (TTM)124.73%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%98.72%

Revenue 1Y (TTM)6.99%

Revenue growth 3Y-26.11%

Revenue growth 5Y-22.75%

Sales Q2Q%-11.72%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 0.06 indicates a rather cheap valuation of SXTC.

Based on the Price/Earnings ratio, SXTC is valued cheaper than 99.49% of the companies in the same industry.

SXTC's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.88.

		Industry Rank	Sector Rank
PE	0.06
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	-2.43

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SXTC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CHINA SXT PHARMACEUTICALS IN

NASDAQ:SXTC (4/30/2025, 8:00:01 PM)

Premarket: 2.34 0 (0%)

2.34

+0.14 (+6.36%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners0.3%

Inst Owner Change136.35%

Ins Owners3.98%

Ins Owner ChangeN/A

Market Cap1.68M

Analysts0

Price TargetN/A

Short Float %7.33%

Short Ratio0.01

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	0.06
Fwd PE	N/A
P/S	0.93
P/FCF	N/A
P/OCF	N/A
P/B	0.11
P/tB	0.11
EV/EBITDA	-2.43

EPS(TTM)40.81

EY1744.02%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-3.77

FCFYN/A

OCF(TTM)-3.76

OCFYN/A

SpS2.53

BVpS20.88

TBVpS20.86

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	18.7%
ROE	38.54%
ROCE	40.41%
ROIC	30.29%
ROICexc	N/A
ROICexgc	N/A
OM	340.71%
PM (TTM)	318.69%
GM	22.02%
FCFM	N/A

ROA(3y)-16.86%

ROA(5y)-21.19%

ROE(3y)-32.52%

ROE(5y)-44.85%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-21.51%

GM growth 5Y-15.27%

F-Score3

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF	N/A
Debt/EBITDA	0.15
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	164.77
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.4
Quick Ratio	1.35
Altman-Z	-0.13

F-Score3

WACC5.71%

ROIC/WACC5.3

Cap/Depr(3y)16.75%

Cap/Depr(5y)40.04%

Cap/Sales(3y)2.08%

Cap/Sales(5y)3.21%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)124.73%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%98.72%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)6.99%

Revenue growth 3Y-26.11%

Revenue growth 5Y-22.75%

Sales Q2Q%-11.72%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y144.87%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-8942.33%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-9119%

OCF growth 3YN/A

OCF growth 5YN/A

CHINA SXT PHARMACEUTICALS IN (SXTC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens